Pfizer, the largest pharmaceutical company in the world, has stopped development of its most promising drug. The move rocked the medical world.
Pfizer invested $800 million and spent 15 years developing torcetrapib.
Cardiologists hoped it would revolutionize heart medicine. Dr. Steven Nissen led one of the earlier studies of torcetrapib. “I had great hopes for this drug. I thought we could make a difference with it. I thought it was going to work. It didn’t.”
The drug was also designed to raise the body’s good cholesterol, or HDL, by about 50 percent.
Pfizer stopped the drug’s final clinical test because 82 people taking it died during the trial, compared to 52 in the control group not taking the drug.
Editors Note: I have written often about the rush to market and the profit motive to of the big pharmaceuticals to develop the next blockbuster drug. Here is just one more example that demonstrates an unspoken attitude and unwritten policy of the big drug companies and the FDA which I call “create it, quickly test it, market it and hope for the best”…so far 82 people have died from this policy and thousands of others are suffering or dead from other drugs that do little to cure and mostly mask symptoms at an incredible financial cost to the taxpayers and unfortunately the an even higher cost those who have died.
- FDA Claims “Cherries” May Now be a Drug
- Natural Alternatives to Statin Drug Use
- Cholesterol Numbers Over 200 Puts You at Greatly Increased Risk for Heart Attacks.
- Congress Looking into Misleading Drug Ads
- An Avalanche of Pharmaceutical Lawsuits and More Coming
- Should Doctors Disclose Financial Ties to Drug Companies?